Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9324324 | 0.77 | — | — | |
| SCHEMBL319993 | 0.77 | — | — | |
| SCHEMBL18976164 | 0.77 | — | — | |
| SCHEMBL28116330 | 0.77 | — | — | |
| SCHEMBL11561961 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL29060489 | 0.76 | MAPT (0.33) | MAPTLMNAMEN1KMT2AGALR3 | |
| SCHEMBL25433762 | 0.74 | — | — | |
| SCHEMBL21544010 | 0.74 | — | — | |
| SCHEMBL7760580 | 0.74 | — | — | |
| SCHEMBL3585568 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4724455-A1 | MULTIVALENT BINDING UNIT MODIFIED DIDEOXYNUCLEOTIDE TRIPHOSPHATES AND METHODS OF MAKING AND USING THE SAME | ILLUMINA, INC. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12590976-B2 | Detection method using both fluorescence and chemiluminescence labels | ACCESS MEDICAL SYSTEMS, LTD. (US) | 2026-03-31 | — | — | US | claimed |
| US-12570716-B2 | Anti-dinitrophenol chimeric antigen receptors | SEATTLE CHILDREN'S HOSPITAL (US) | 2026-03-10 | — | — | US | claimed |
| EP-4306167-B1 | INDUCED EXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) FOR TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL AND/OR METABOLIC DISEASES | MITOCHON PHARMACEUTICALS INC (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4657067-A2 | MOLECULES AND METHODS FOR IMPROVED IMMUNODETECTION OF SMALL MOLECULES, SUCH AS HISTAMINE | President And Fellows Of Harvard College (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250354204-A1 | AUTOMATED RNA DETECTION USING LABELED 2'-O-METHYL RNA OLIGONUCLEOTIDE PROBES AND SIGNAL AMPLIFICATION SYSTEMS | VENTANA MED SYST INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025227129-A2 | DELIVERY VEHICLES COMPRISING PROGLUCAGON DERIVED POLYPEPTIDES AND ANABOLIC POLYPEPTIDES AND USES THEREOF | STARROCK PHARMA LLC (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4638775-A1 | ASSAY METHODS AND KITS | Meso Scale Technologies, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2025217089-A1 | ODORIZED FLUIDS AND METHODS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-10-16 | — | — | WO | claimed |
| EP-2444806-A2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | Ventana Medical Systems, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2444807-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2130821-B1 | Derivatives of 3,4,5-trinitropyrazole, their preparation and the energetic compositions containing them | SME (FR) | 2011-09-21 | — | — | EP | claimed |
| EP-2155688-A2 | DINITROPYRAZOLE DERIVATIVES, THEIR PREPARATION, AND ENERGETIC COMPOSITIONS COMPRISING THEM. | SNPE Matériaux Energétiques (FR) | 2010-02-24 | — | — | EP | claimed |
| EP-2130821-A1 | Derivatives of 3,4,5-trinitropyrazole, their preparation and the energetic compositions containing them | SNPE Matériaux Energétiques (FR) | 2009-12-09 | — | — | EP | claimed |
| US-20090186931-A1 | Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them | ARIANEGROUP SAS (FR) | 2009-07-23 | — | — | US | claimed |
| EP-2078197-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008152525-A2 | DINITROPYRAZOLE DERIVATIVES, THEIR PREPARATION, AND ENERGETIC COMPOSITIONS COMPRISING THEM. | SNPE MATERIAUX ENERGETIQUES (FR) | 2008-12-18 | — | — | WO | claimed |
| WO-2008063378-A9 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2008-07-31 | — | — | WO | claimed |
| WO-2008063378-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570716-B2 | Anti-dinitrophenol chimeric antigen receptors | CD2, CD2BP2, LY96 | GPR35 1746/4885MAPT 2236/4885CYP3A4 4191/4885 |
| US-12590976-B2 | Detection method using both fluorescence and chemiluminescence labels | CD14, FLT4, FLT1 | GPR35 3479/4885MAPT 1381/4885CYP3A4 3246/4885 |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | DNPH1, SLC5A2, DNPEP | GPR35 2262/4885MAPT 1766/4885CYP3A4 149/4885 |
| US-20090186931-A1 | Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them | NQO2, HRH4, NFE2L2 | GPR35 1027/4885MAPT 3611/4885CYP3A4 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.